NCT03697603View on ClinicalTrials.gov

A Study of Brexpiprazole in Patients With Major Depressive Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

June 6, 2022

Study Completion Date

July 4, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

Brexpiprazole

Tablets, Oral, once daily, 14 weeks

DRUG

Placebo

Tablets, Oral, once daily, 14 weeks

Trial Locations (1)

Unknown

Nanko-kokorono clinic, Fukushima

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT03697603 - A Study of Brexpiprazole in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter